<DOC>
	<DOCNO>NCT02298088</DOCNO>
	<brief_summary>Administration TicagRElor pAtients ST elevation myocardial infarction treat pharmacological Thrombolysis</brief_summary>
	<brief_title>Ticagrelor Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis</brief_title>
	<detailed_description>A Phase III , Randomized , Multicenter , Open label , Blinded Adjudication Outcomes , Non-Inferiority Clinical Trial Explore Safety Efficacy Ticagrelor Compared Clopidogrel Patients Acute Coronary Syndrome ST Elevation Treated Pharmacological Thrombolysis - TREAT</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Patients sex age â‰¥ 18 year &lt; 75 year ACS ST segment elevation onset previous 24 hour , document cardiac ischemic symptom due atherosclerosis &gt; 10 minute duration rest , treat pharmacological thrombolysis Fibrinolytic therapy give patient STEMI onset ischemic symptom within previous 12 hour Patients acute coronary syndrome ST segment elevation include provided present ST segment elevation J point two contiguous lead electrocardiogram cutpoints : &gt; 0.1mV lead lead V2V3 , follow cut point apply : &gt; 0.2 mV men &gt; 40 year ; &gt; 0.25 mV men &lt; 40 year , &gt; 0.15 mV woman least 1 follow criterion : Anginalike chest pain ischemic equivalent chest pain ; Abnormalities reference value marker myocardial necrosis ( troponin CKMB ) . The patient must able give informed consent accordance ICH GCP guideline local legislation and/or regulation . Any contraindication use clopidogrel ( eg , hypersensitivity , moderate severe liver disease , active bleeding bleed history , history intracranial hemorrhage ) Need oral anticoagulation therapy , Concomitant oral IV therapy strong CYP3A inhibitor ( ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir , grapefruit juice N1 L/d ) , CYP3A substrates narrow therapeutic index ( cyclosporine , quinidine ) , strong CYP3Ainducers ( rifampin/rifampicin , phenytoin , carbamazepine ) Increased risk bradycardia event Dialysis require Known clinically important thrombocytopenia Known clinically important anemia Any condition may put patient risk influence study result investigator ' opinion ( eg , cardiogenic shock , severe hemodynamic instability , active cancer ) Participant another investigational drug device study within 30 Pregnancy lactation Any condition increase risk noncompliance lose followup Involvement planning conduct study Previous enrollment randomization study Contraindications fibrinolytic therapy include : 15 Any prior intracranial hemorrhage Known structural cerebral vascular lesion ( eg , Arterial Venous Malformation AVM ) Known malignant intracranial neoplasm ( primary metastatic ) Ischemic stroke within 3 month Suspected aortic dissection Active bleeding bleed diathesis ( exclude menses ) Significant close head trauma facial trauma within 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>